ORION Biotech Catalyst Calendar
Menu
Skip to company dates

Altimmune (ALT) pipeline and stated timing

No current calendar date is shown here. Retained program statements and source dates appear below.

Programs and stated timing

○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.

No source-verified calendar row is retained.

How this date was described over time

Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .

No additional verified wording history is retained.

“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.

Retained company announcements

Historical summaries and source dates are retained separately from the SEC timing quotes above. Earlier publications were collected retrospectively.

Historical catalog checked .

MOMENTUM Phase 2 48-week results

Q1 2023 update: MOMENTUM timing

Source published · Original announcement

Retained timing label: 2023

Retained summary: Altimmune expected the 48-week results of the MOMENTUM Phase 2 obesity trial in the fourth quarter of 2023.

Retained source and collection times
Event effective
UNAVAILABLE
ORION first seen
ORION ingested

MOMENTUM 48-week topline announcement

Source published · Original announcement

Retained summary: Altimmune announced the 48-week MOMENTUM topline results on November 30, 2023. This records publication of the readout, not an ORION efficacy comparison or investment recommendation.

Retained source and collection times
Event effective
ORION first seen
ORION ingested

Read the retained source trail

Selected registry record

No selected registry study is connected in this retained catalog.

Scope of retained company and registry evidence

These are selected linked records and dated source metadata, not a live registry recheck or the company’s full pipeline. Company announcements and the selected registry study are separate evidence sets. No stage or event timing is borrowed between them.

Coverage and identity checks

Watch ALT

Or email ORION to ask for this Watch.

Request another SEC timing statement

Suggest an SEC timing statement to add for ALT. You can include the original filing link in your note. The founder reads each request by hand.

Or email ORION.

Reading these records

First stated window
The timing wording in the earliest company statement located within the sources checked, quoted as written (for example “2H 2026”). An earlier statement may exist outside those sources.
Disclosure date
The date of the filing or company release that disclosed the readout. “None found” means no such disclosure was located in the sources checked. SEC filings were searched through the “SEC filings searched through” date shown.
1H, 2H, 1Q–4Q
First or second half, or first to fourth quarter, of the year named, as the company wrote it. Equivalent notations are compared together; the original wording stays visible.
SEC original
The filing as published on the SEC EDGAR system. “Company original” is the release on the company's own investor site.
Status
One of seven labels set by founder review of the original filings. Definitions: Methodology.

See ALT in the calendar · Review labels and methodology

Q1–Q4 (also written 1Q–4Q) are quarters of the year: Q1 is January–March, Q2 April–June, Q3 July–September and Q4 October–December, unless the company uses a different fiscal year.Topline results are the main summary results of a clinical trial, released before the full data.